Laborie Announces First Procedures in ENDURE 1 Study with the Optilume® Ureteric Drug-Coated Balloon
Landmark procedures launch the ENDURE 1 clinical study evaluating Optilume's safety and feasibility as a new minimally invasive option for patients with benign ureteric strictures. PORTSMOUTH, N.H., ...
Optilume BPH is expected to have a significant global impact in urology, offering a novel alternative treatment option for enlarged prostate "We are proud at University Urology Associates to be ...
Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic hyperplasia (BPH), concludes a ...
The approval represents an important milestone in establishing the reimbursement pathway for this novel technology in the U.S. PORTSMOUTH, N.H., Nov. 7, 2022 /PRNewswire/ -- Laborie Medical ...
The MarketWatch News Department was not involved in the creation of this content. Landmark procedures launch the ENDURE 1 clinical study evaluating Optilume's safety and feasibility as a new minimally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback